Penn spinout Verismo Therapeutics was featured in the Philadelphia Business Journal. The cell therapy startup recently raised $17 million to advance its lead immunotherapy candidates in a second pre-Series A round of funding.
Along with CEO Bryan Kim, DMD, Penn faculty Michael Milone, PhD, MD, Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania and Associate Director, Toxicology Laboratory at Penn Medicine, and Donald Siegel, PhD, MD, Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania and Director, Division of Transfusion Medicine and Therapeutic Pathology, founded Verismo in 2020.
Verismo plans to utilize the new funding to further advance multiple programs it has for immunotherapy candidates including SynKIR-100 for solid tumors including, ovarian cancer and bile duct cancer as well as SynKIR-310 for blood cancers. Read the full article here.